In feed mill applications, the veterinary-grade API containing live Bifidobacterium, Lactobacillus acidophilus, Streptococcus faecalis (current taxonomic designation Enterococcus faecalis), and yeast preparation is standardized before inclusion. The freeze-dried biomass is blended with maltodextrin or microcrystalline cellulose to a target count of 1 × 10¹⁰ CFU/g to 1 × 10¹¹ CFU/g. The blend is introduced into a horizontal ribbon mixer or vertical screw mixer at a fill ratio of 0.6 and mixed for 8 min to 12 min. Batch-to-batch uniformity is confirmed by sampling at 10 defined points per mixer using ISO 6887-1:2017 preparation and ISO 4833-1:2013 enumeration. A coefficient of variation below 10% is the release limit. In this operation, viability loss arises primarily from mechanical attrition and moisture migration, not from oxidative degradation alone.

The main process conflict occurs during pellet conditioning. When mash is conditioned at 75 °C or above, published single-strain studies report 1 log to 3 log CFU/g reductions for Lactobacillus acidophilus, with Bifidobacterium showing greater heat sensitivity. Therefore, dry inclusion through the mixer is restricted to unheated mash or extruded feeds with a die temperature below 60 °C and product moisture below 12%. Post-pellet liquid application is preferred at 0.1% to 0.5% w/w of finished feed. The yeast fraction, typically Saccharomyces cerevisiae or a yeast cell-wall preparation, survives pellet conditioning better than the bacterial components, but label claims cannot be based on yeast recovery alone. Premix stored at 25 °C and 60% relative humidity should be consumed within 30 days unless real-time stability data support a longer hold; moisture uptake above 0.20 water activity initiates metabolic activity and shortens batch life.

Which Measured Water Parameters Trigger Rapid Loss of Bifidobacterium Viability in Drinking-Water Delivery Systems?

In poultry and swine barns, the API is dispersed through a proportioner dosing pump into drinking water at a final concentration of 1 × 10⁶ CFU/mL to 1 × 10⁷ CFU/mL. The critical variables are water temperature, residual oxidizer concentration, and pH. At water temperatures above 25 °C, viability loss in static distribution lines exceeds 0.5 log CFU/mL over 4 h. Residual chlorine at 0.2 mg/L to 0.5 mg/L, which is routine for potable water, reduces Bifidobacterium populations by more than 1 log within 30 min. Dosing systems therefore include an upstream dechlorination step using ascorbic acid or sodium thiosulfate at a stoichiometric excess of 1.1× to 1.3× relative to the measured oxidant residual. Solution pH is maintained between 5.5 and 6.5; below 4.5, Lactobacillus acidophilus undergoes acid stress, and above 8.0 the yeast fraction can settle and promote biofilm adhesion. Recirculation loops are operated at 0.5 m/s to 1.0 m/s to reduce sedimentation. The reconstituted suspension is consumed within 6 h. Viability is confirmed before and after the stated contact time using ISO 29981:2010 for Bifidobacterium, ISO 20128:2006 for Lactobacillus acidophilus, ISO 7899-2:2000 for Enterococcus faecalis, and ISO 21527-1:2008 for yeast. If total viable count after 6 h deviates more than 0.5 log from the initial count, the water line is not considered suitable for live microbial delivery without additional treatment.

In companion animal supplement manufacturing, the spray-dried or freeze-dried API is filled into hard capsules or compressed into tablets. The freeze-dried cake is milled to a particle size distribution with D90 below 200 μm; larger agglomerates produce visible specks in capsule shells and increase segregation in compression hoppers. Capsule filling is performed on low-shear dosator or tamping pin machines rather than high-speed rotary auger fillers because the fragile bacterial matrix is sensitive to fill shoe compression. Fill weight is adjusted to deliver 1 × 10⁹ CFU to 1 × 10¹⁰ CFU per capsule, with an overage of 20% to 40% depending on shell moisture barrier properties. Hard HPMC capsules are conditioned at 35% to 45% relative humidity before filling; below 30% relative humidity, electrostatic charging reduces fill weight accuracy, and above 50% relative humidity, water uptake can initiate metabolic activity.

For direct-compression tablets, a force range of 5 kN to 10 kN is applied on flat-faced beveled tooling. Higher compression forces densify the matrix and can reduce rehydration porosity, but published data do not show a linear relationship between compression force and total viable count. The powder blend is dried to water activity below 0.20 and tableting is completed within 4 h of final blending. Disintegration is assessed by Ph. Eur. 2.9.1; a disintegration time below 30 minutes in water at 37 °C is considered acceptable, but the live-cell claim requires microbial enumeration after disintegration, not solely tablet breakdown.

When Low-Dew-Point Inlet Air Is Used in Top-Spray Granulation of the Four-Strain API

Granules for veterinary oral solutions or feed top-dress use are prepared in a top-spray fluidized-bed coater with a 5 kg to 20 kg batch capacity. The API is suspended in a binder solution prepared with hydroxypropyl methylcellulose or starch at 2% to 5% w/w. Inlet air is set at 45 °C and product temperature is held at 30 °C to 35 °C; the use of low-dew-point inlet air below 4 °C reduces moisture load but increases electrostatic buildup on the expansion chamber. Spray rate is adjusted to keep bed relative humidity below 20%. Atomizing air pressure of 1.0 bar to 1.5 bar is typical for a 1.2 mm two-fluid nozzle; higher shear at the nozzle can rupture bacterial cells, with viability losses exceeding 0.5 log when atomizing pressure exceeds 1.5 bar.

After spraying, the granules are dried to a loss on drying of 2.0% to 3.0% and a water activity of 0.15 to 0.25. Agglomerates with D50 between 150 μm and 500 μm show acceptable flow and dispersibility. Viability is checked after granulation using the organism-specific enumeration methods. The main batch failure mode is localized overwetting, which causes yeast cells to germinate and bacterial cells to leach from the granule matrix; this is controlled by monitoring exhaust air humidity and product temperature rather than inlet air alone. Equipment cleaned with chlorinated water must be dried to below 0.20 water activity before the next batch because residual chlorine at 0.2 mg/L can reduce viability during the start-up phase.

In a feed mill running a medicated line containing tetracycline-class antibiotics, the four-strain API is not added to the same mixer or pellet line without a validated flush sequence. Enterococcus faecalis and Lactobacillus acidophilus are susceptible to tetracyclines; susceptibility testing by broth microdilution using CLSI VET01 documents enterococcal chlortetracycline MICs below 8 μg/mL for some isolates, but in-feed compatibility is matrix-dependent and cannot be inferred from MIC data alone. The production sequence places the probiotic premix at the end of the campaign, after a flush with ground corn or rice hulls equivalent to 2% to 5% of mixer capacity. Cleanout effectiveness is measured by residual antibiotic assay, with an acceptance limit below 1% of the lowest therapeutic dose. If carryover exceeds 0.1% w/w in the subsequent batch, bacterial label claims may not be met. The yeast fraction often remains viable in the presence of antibacterial compounds, but the bacterial components define the product claim. This sequencing is consistent with equipment cleanout requirements in 21 CFR 225 and feed additive authorization under EU Regulation 1831/2003. Where monensin is present at 100 g/ton, published data for this specific four-strain blend is limited; compatibility must be confirmed by a batch-specific recovery study rather than assumed from single-strain minimum inhibitory concentration data.

Injectable Manufacturing with a Live Four-Strain Veterinary API: Terminal Sterilization and Filtration Boundaries

Injectable dosage forms containing viable Bifidobacterium, Lactobacillus acidophilus, Enterococcus faecalis, and yeast cells do not conform to standard pharmacopoeial parenteral requirements. A terminal sterilization cycle of 121 °C for 15 minutes produces a 6-log reduction of mesophilic organisms but also eliminates the live-cell claim and leaves nonviable cell debris that can raise pyrogen load. Sterile filtration through a 0.22 μm membrane retains all four microbial fractions, yielding a cell-free filtrate. If an injectable product is manufactured from this API, the viable-cell content is not the active principle after filtration; the filtrate may contain soluble metabolic products, but this is a separate product definition requiring its own specification.

Intravenous or intramuscular administration of viable cells creates risk of sepsis, embolism, and immune-mediated reaction. Injectable applications are therefore limited to research, antigen preparation after inactivation, or cell-free filtrates with supporting safety data. Pyrogen testing follows Ph. Eur. 2.6.14 or USP <85>; particulate matter follows Ph. Eur. 2.9.19 or USP <788>. The API batch record must document viability before processing, but the injectable finished product specification cannot include a live-cell count.

For calf and lamb oral drench preparations, the API is dispersed in an aqueous vehicle containing 0.5% to 1.0% sodium carboxymethylcellulose and 2% to 5% glycerol or propylene glycol. The drench is filled into single-dose syringes or bottles at 1 × 10⁹ CFU to 5 × 10⁹ CFU per dose. Osmolality is maintained below 600 mOsm/kg to reduce osmotic shock to Bifidobacterium and Lactobacillus acidophilus; pH is buffered to 5.0 to 6.0 with citrate or phosphate buffer. The preparation is stored at 2 °C to 8 °C and used within 72 h after compounding. In milk replacer applications, the API is not mixed with hot milk above 45 °C or with reconstituted milk replacer that contains subtherapeutic levels of tetracycline. Co-administration with oral rehydration solutions containing bicarbonate or high concentrations of electrolytes above 400 mOsm/kg may reduce viable counts; published data for this specific four-strain blend in hypertonic oral rehydration solutions is limited, so mixing studies are required before batch release.